Overview
Sun Pharmaceutical Industries combines a large, internationally active medicines business with growth and profitability in the supplied figures. Revenue is INR 599.1B, up 10.50%, and the reported profit margin is 20.19%. At INR 1,781.00, the share is within its 52-week range but below its 50-day and 200-day moving averages. Its P/E ratio of 35.31 and 0.00% dividend yield add important context for Australian investors assessing the company’s business profile and valuation.
Sun Pharmaceutical Industries is an India-based drug manufacturer with operations spanning branded and generic formulations, specialty medicines and active pharmaceutical ingredients. Its products cover a wide range of therapeutic areas, including cardiology, diabetes, dermatology, oncology and neuropsychiatry, alongside over-the-counter products. The company sells in India, the United States and international markets. The supplied figures show revenue of INR 599.1B, growth of 10.50% and a profit margin of 20.19%, pointing to a business with both meaningful scale and a broad operating footprint.
Key facts
- Ticker
- SUNPHARMA
- Exchange
- NSE
- ISIN
- INE044A01036
- Sector
- Healthcare
- Industry
- Drug Manufacturers – Specialty & Generic
- Country
- India
- Currency
- INR
- Price
- INR 1,781.00
- Previous close
- INR 1,804.10
- Day change
- -INR 23.10 (-1.28%)
- Market cap
- 4.3T
- 52W low
- INR 1,569.37
- 52W high
- INR 2,046.90
Price and trend
Last price: INR 1,781.00
- Price
- INR 1,781.00
- 52W range
- INR 1,569.37 – INR 2,046.90
- 50-day SMA
- INR 1,897.33
- 200-day SMA
- INR 1,807.88
- Price vs 50D SMA
- -6.13%
- Price vs 200D SMA
- -1.49%
Valuation
- P/E
- 35.31
- PEG
- 1.04
- EPS
- 51.09
- Dividend yield
- 0.00%
- Beta
- 0.14
At a market capitalisation of 4.3T and a P/E ratio of 35.31, Sun Pharmaceutical is valued on a substantial earnings multiple. Its PEG ratio of 1.04 provides another reference point alongside revenue growth of 10.50% and a profit margin of 20.19%; these measures should be considered together rather than in isolation. The supplied analyst target price is INR 2,171.53, or 21.93% from the last price. That is secondary context, not a forecast or a guarantee of future performance. The supplied dividend yield is 0.00%.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Profitability and growth
- Revenue growth
- 10.50%
- Revenue TTM
- 599.1B
- Profit margin
- 20.19%
Analyst view
Comparison uses the last price shown; targets are analyst estimates.
- Price
- INR 1,781.00
- Target price
- INR 2,171.53
- Target vs last price
- 21.93% from last price
The operating picture combines 10.50% revenue growth with a 20.19% profit margin, while the company’s broad portfolio and geographic reach provide context for its scale. On the share-price side, SUNPHARMA was at INR 1,781.00, down 1.28% from the previous close. It remained within its 52-week range of INR 1,569.37 to INR 2,046.90, but sat 6.13% below its 50-day moving average and 1.49% below its 200-day average. These technical measures offer recent price context rather than a conclusion about the company’s longer-term prospects.
Risks
Sun Pharmaceutical’s broad portfolio and international reach do not remove the risks of operating in a highly regulated, competitive pharmaceutical industry. Its performance can be affected by product and market competition, regulatory requirements, and the execution needed to develop and sell medicines across therapeutic areas and countries. The share price is below its supplied 50-day and 200-day moving averages, while its P/E ratio of 35.31 means valuation expectations are also relevant to how investors assess the business. The supplied dividend yield is 0.00%, so the share does not currently present a dividend yield in these figures.
FAQ
What does Sun Pharmaceutical Industries do?
Sun Pharmaceutical Industries develops, manufactures and markets branded and generic medicines, specialty medicines and active pharmaceutical ingredients. Its products span a broad range of therapeutic areas and are sold in India, the United States and other international markets.
How has Sun Pharmaceutical been growing?
The supplied figures show revenue of INR 599.1B and revenue growth of 10.50%. Its reported profit margin is 20.19%, indicating the company has paired growth with substantial profitability in the period represented by the data.
Does Sun Pharmaceutical pay a dividend?
The supplied dividend yield is 0.00%, so the figures do not indicate a current dividend yield. The company’s profile is more centred on its pharmaceutical operations and financial performance than on dividend income.
How does SUNPHARMA compare with its recent trading range?
At INR 1,781.00, the share price is within its 52-week range of INR 1,569.37 to INR 2,046.90. It is below both the 50-day moving average of INR 1,897.33 and the 200-day moving average of INR 1,807.88.
*This content is aimed to provide general information only, and does not take your personal objectives, financial situation or needs into account.
